<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2023-361-368</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-3364</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Нужно оценить эффективность терапии? Спросите пациента!</article-title><trans-title-group xml:lang="en"><trans-title>Need to assess the effect of therapy? Ask the patient!</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5103-5447</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полищук</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Polishchuk</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><email xlink:type="simple">dr.pogozheva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1391-0711</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каратеев</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Karateev</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8627-5341</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Потапова</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Potapova</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2475-8620</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Филатова</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Filatova</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6334-2903</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хлабощина</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Khlaboshchina</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5382-6357</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Амирджанова</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Amirjanova</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6068-3080</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лила</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lila</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а;125993, Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A; 125993, Moscow, Barrikadnaya str., 2/1, building 1</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»;&#13;
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology;&#13;
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>29</day><month>06</month><year>2023</year></pub-date><volume>61</volume><issue>3</issue><fpage>361</fpage><lpage>368</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Полищук Е.Ю., Каратеев А.Е., Потапова А.С., Филатова Е.С., Хлабощина В.Н., Амирджанова В.Н., Лила А.М., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Полищук Е.Ю., Каратеев А.Е., Потапова А.С., Филатова Е.С., Хлабощина В.Н., Амирджанова В.Н., Лила А.М.</copyright-holder><copyright-holder xml:lang="en">Polishchuk E.Y., Karateev A.E., Potapova A.S., Filatova E.S., Khlaboshchina V.N., Amirjanova V.N., Lila A.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/3364">https://rsp.mediar-press.net/rsp/article/view/3364</self-uri><abstract><p>Достижение хорошего результата лечения ревматических заболеваний (РЗ) требует регулярного динамического наблюдения за состоянием пациентов и коррекции проводимой терапии при ее недостаточной эффективности или непереносимости. При этом оценка состояния больных должна основываться на четких критериях, позволяющих объективизировать основные проявления болезни. Для этого применяется расчет стандартных индексов активности и тяжести РЗ (DAS28, CDAI, SDAI, BASDAI, ASDAS, DAPSA, PsARC, PASI и др.). Однако такая методика не всегда позволяет оценить принципиально важные параметры результата лечения – удовлетворенность и хорошее самочувствие пациента. Согласно данным серии исследований, недостаточная удовлетворенность проводимой терапией может отмечаться у ≈25% пациентов с системными РЗ, которые находятся в состоянии ремиссии/низкой воспалительной активности по стандарт ным индексам. Более того, в 20–30% случаев имеется серьезное расхождение в оценках результатов терапии между пациентом и его лечащим врачом. Поэтому более точная оценка состояния пациента требует, помимо расчета стандартных индексов, обязательного анализа показателей, оцениваемых самим пациентом – боли, нарушения функции, общей оценки активности заболевания, усталости (утомляемости) и др. Ценным инструментом для определения самочувствия и хорошего результата терапии с точки зрения самого пациента является PASS (Patient Acceptable Symptom State, состояние симптомов, приемлемое для пациента). Этот простой и достаточно информативный показатель хорошо коррелирует с основными симптомами и параметрами ремиссии/низкой активности РЗ. Анализ PASS может использоваться при телемедицинском контроле состояния больных, когда невозможно провести их объективное обследование. Совместное использование PASS и стандартных индексов позволяет лучше оценить результаты лечения и повысить качество жизни пациентов с РЗ.</p></abstract><trans-abstract xml:lang="en"><p>Achieving a good treatment outcome in rheumatic diseases (RD) requires regular, dynamic patient monitoring and therapy correction if it is not effective or intolerant. The patient assessment must be based on clear criteria to objectify the main manifestations of the disease. For this purpose, the calculation of standard activity and severity indices (DAS28, CDAI, SDAI, BASDAI, ASDAS, DAPSA, PsARC, PASI, etc.) is used. However, this methodology does not always allow the assessment of the fundamentally important parameters of treatment outcome – patient satisfaction and well-being. According to a series of studies, poor therapy satisfaction may be observed in ≈25% of patients with systemic RD who are in remission/low disease activity according to standard indices. Moreover, in 20–30% of cases there is a major discrepancy in the assessment of therapy outcome between the patient and physician. Therefore, a more accurate assessment of the patient’s condition requires, in addition to the calculation of standard indices, the mandatory analysis of patient-reported outcomes – pain, functional impairment, general assessment of disease activity, fatigue, etc. A valuable tool for determining well-being and good therapy outcome from the patient’s point of view is the PASS (“patient acceptable symptom state”). This simple and quite informative index correlates well with core symptoms and indicators of remission/low disease activity. PASS analysis can be used in telemedicine follow-up of patients when an objective examination is not possible. The combined use of PASS and standardized indices can better assess treatment outcomes and improve the quality of life of patients with RD.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ревматические заболевания</kwd><kwd>ревматоидный артрит</kwd><kwd>оценка активности</kwd><kwd>показатели</kwd><kwd>оцениваемые пациентом</kwd><kwd>PASS</kwd></kwd-group><kwd-group xml:lang="en"><kwd>rheumatic diseases</kwd><kwd>rheumatoid arthritis</kwd><kwd>disease activity</kwd><kwd>patient-reported outcomes</kwd><kwd>PASS</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках фундаментальной темы FURS2022-008 (номер государственного задания: 1021051503137-7). Исследование не имело спонсорской под держки.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ (ред). Ревматология: Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2020.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL (ed). Rheumatology: Russian clinical recommendations Moscow:GEOTAR-Media;2020 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Лила АМ. Ревматоидный артрит: достижения и нерешенные проблемы. Терапевтический архив. 2019;91(5):4-7. doi: 10.26442/00403660.2019.05.000259</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Lila AM. Rheumatoid arthritis: Achievements and unresolved issues. Terapevticheskii arkhiv. 2019;91(5):4-7 (In Russ.). doi: 10.26442/00403660.2019.05.000259</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3):263-271. doi: 10.14412/1995-4484-2018-263-271</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid arthritis: The problems of remission and therapy resistance. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(3): 363-271 (In Russ.). doi: 10.14412/1995-4484-2018-263-271</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019. doi: 10.1136/rmdopen-2014-000019</mixed-citation><mixed-citation xml:lang="en">Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019. doi: 10.1136/rmdopen-2014-000019</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor PC, Woods M, Rycroft C, Patel P, Blanthorn-Hazell S, Kent T, et al. Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom. Rheumatology (Oxford). 2021;60(11):4972-4981. doi: 10.1093/rheumatology/keab464</mixed-citation><mixed-citation xml:lang="en">Taylor PC, Woods M, Rycroft C, Patel P, Blanthorn-Hazell S, Kent T, et al. Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom. Rheumatology (Oxford). 2021;60(11):4972-4981. doi: 10.1093/rheumatology/keab464</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Smolen JS, Strand V, Koenig AS, Szumski A, Kotak S, Jones TV. Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Res Ther. 2016;18(1):114. doi: 10.1186/s13075-016-1004-3</mixed-citation><mixed-citation xml:lang="en">Smolen JS, Strand V, Koenig AS, Szumski A, Kotak S, Jones TV. Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Res Ther. 2016;18(1):114. doi: 10.1186/s13075-016-1004-3</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Desthieux C, Granger B, Balanescu AR, Balint P, Braun J, Canete JD, et al. Determinants of patient-physician discordance in global assessment in psoriatic arthritis: A multicenter European study. Arthritis Care Res (Hoboken). 2017;69(10):1606-1611. doi: 10.1002/acr.23172</mixed-citation><mixed-citation xml:lang="en">Desthieux C, Granger B, Balanescu AR, Balint P, Braun J, Canete JD, et al. Determinants of patient-physician discordance in global assessment in psoriatic arthritis: A multicenter European study. Arthritis Care Res (Hoboken). 2017;69(10):1606-1611. doi: 10.1002/acr.23172</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Desthieux C, Molto A, Granger B, Saraux A, Fautrel B, Gossec L. Patient-physician discordance in global assessment in early spondyloarthritis and its change over time: The DESIR cohort. Ann Rheum Dis. 2016;75(9):1661-1666. doi: 10.1136/annrheumdis-2015-208251</mixed-citation><mixed-citation xml:lang="en">Desthieux C, Molto A, Granger B, Saraux A, Fautrel B, Gossec L. Patient-physician discordance in global assessment in early spondyloarthritis and its change over time: The DESIR cohort. Ann Rheum Dis. 2016;75(9):1661-1666. doi: 10.1136/annrheumdis-2015-208251</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Desthieux C, Hermet A, Granger B, Fautrel B, Gossec L. Patientphysician discordance in global assessment in rheumatoid arthritis: A systematic literature review with meta-analysis. Arthritis Care Res (Hoboken). 2016;68(12):1767-1773. doi: 10.1002/acr.22902</mixed-citation><mixed-citation xml:lang="en">Desthieux C, Hermet A, Granger B, Fautrel B, Gossec L. Patientphysician discordance in global assessment in rheumatoid arthritis: A systematic literature review with meta-analysis. Arthritis Care Res (Hoboken). 2016;68(12):1767-1773. doi: 10.1002/acr.22902</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Guimarães MFBR, Pinto MRDC, Resende GG, Machado CJ, Vargas-Santos AB, Amorim RBC, et al. Discordance between the patient’s and physician’s global assessment in rheumatoid arthritis: Data from the REAL study-Brazil. PLoS One. 2020;15(3):e0230317. doi: 10.1371/journal.pone.0230317</mixed-citation><mixed-citation xml:lang="en">Guimarães MFBR, Pinto MRDC, Resende GG, Machado CJ, Vargas-Santos AB, Amorim RBC, et al. Discordance between the patient’s and physician’s global assessment in rheumatoid arthritis: Data from the REAL study-Brazil. PLoS One. 2020;15(3):e0230317. doi: 10.1371/journal.pone.0230317</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wei W, Sullivan E, Blackburn S, Chen CI, Piercy J, Curtis JR. The prevalence and types of discordance between physician perception and objective data from standardized measures of rheumatoid arthritis disease activity in real-world clinical practice in the US. BMC Rheumatol. 2019;3:25. doi: 10.1186/s41927-019-0073-8</mixed-citation><mixed-citation xml:lang="en">Wei W, Sullivan E, Blackburn S, Chen CI, Piercy J, Curtis JR. The prevalence and types of discordance between physician perception and objective data from standardized measures of rheumatoid arthritis disease activity in real-world clinical practice in the US. BMC Rheumatol. 2019;3:25. doi: 10.1186/s41927-019-0073-8</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Saag KG. OMERACT 6 brings new perspectives to rheumatology measurement research. J Rheumatol. 2003;30(4):639-641.</mixed-citation><mixed-citation xml:lang="en">Saag KG. OMERACT 6 brings new perspectives to rheumatology measurement research. J Rheumatol. 2003;30(4):639-641.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Alves Pereira I, Maldonado Cocco J, Feijó Azevedo V, Guerra G, Bautista-Molano W, Casasola JC, et al. Levels of satisfaction with rheumatoid arthritis treatment and associated alignment between physicians and patients across Latin America. Clin Rheumatol. 2020;39(6):1813-1822. doi: 10.1007/s10067-019-04858-x</mixed-citation><mixed-citation xml:lang="en">Alves Pereira I, Maldonado Cocco J, Feijó Azevedo V, Guerra G, Bautista-Molano W, Casasola JC, et al. Levels of satisfaction with rheumatoid arthritis treatment and associated alignment between physicians and patients across Latin America. Clin Rheumatol. 2020;39(6):1813-1822. doi: 10.1007/s10067-019-04858-x</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Furst DE, Tran M, Sullivan E, Pike J, Piercy J, Herrera V, et al. Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control. Clin Rheumatol. 2017;36(9):2045-2054. doi: 10.1007/s10067-017-3578-9</mixed-citation><mixed-citation xml:lang="en">Furst DE, Tran M, Sullivan E, Pike J, Piercy J, Herrera V, et al. Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control. Clin Rheumatol. 2017;36(9):2045-2054. doi: 10.1007/s10067-017-3578-9</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">De Mits S, Lenaerts J, Vander Cruyssen B, Mielants H, Westhovens R, Durez P, et al.; Be-Raise study group. A nationwide survey on patient’s versus physician’s evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration: The Be-Raise study. PLoS One. 2016;11(11):e0166607. doi: 10.1371/journal.pone.0166607</mixed-citation><mixed-citation xml:lang="en">De Mits S, Lenaerts J, Vander Cruyssen B, Mielants H, Westhovens R, Durez P, et al.; Be-Raise study group. A nationwide survey on patient’s versus physician’s evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration: The Be-Raise study. PLoS One. 2016;11(11):e0166607. doi: 10.1371/journal.pone.0166607</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Schäfer M, Albrecht K, Kekow J, Rockwitz K, Liebhaber A, Zink A, et al. Factors associated with treatment satisfaction in patients with rheumatoid arthritis: Data from the biological register RABBIT. RMD Open. 2020;6(3):e001290. doi: 10.1136/rmdopen-2020-001290</mixed-citation><mixed-citation xml:lang="en">Schäfer M, Albrecht K, Kekow J, Rockwitz K, Liebhaber A, Zink A, et al. Factors associated with treatment satisfaction in patients with rheumatoid arthritis: Data from the biological register RABBIT. RMD Open. 2020;6(3):e001290. doi: 10.1136/rmdopen-2020-001290</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Fujiwara T, Kondo M, Yamada H, Haraguchi A, Fujimura K, Sakuraba K, et al. Factors affecting patient satisfaction related to cost and treatment effectiveness in rheumatoid arthritis: Results from the multicenter observational cohort study, FRANK Registry. Arthritis Res Ther. 2022;24(1):53. doi: 10.1186/s13075-022-02746-5</mixed-citation><mixed-citation xml:lang="en">Fujiwara T, Kondo M, Yamada H, Haraguchi A, Fujimura K, Sakuraba K, et al. Factors affecting patient satisfaction related to cost and treatment effectiveness in rheumatoid arthritis: Results from the multicenter observational cohort study, FRANK Registry. Arthritis Res Ther. 2022;24(1):53. doi: 10.1186/s13075-022-02746-5</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Alcaide L, Torralba AI, Eusamio Serre J, García Cotarelo C, Loza E, Sivera F. Current state, control, impact and management of rheumatoid arthritis according to patient: AR 2020 national survey. Reumatol Clin (Engl Ed). 2022;18(3):177-183. doi: 10.1016/j.reumae.2021.03.002</mixed-citation><mixed-citation xml:lang="en">Alcaide L, Torralba AI, Eusamio Serre J, García Cotarelo C, Loza E, Sivera F. Current state, control, impact and management of rheumatoid arthritis according to patient: AR 2020 national survey. Reumatol Clin (Engl Ed). 2022;18(3):177-183. doi: 10.1016/j.reumae.2021.03.002</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Tveit KS, Duvetorp A, Østergaard M, Skov L, Danielsen K, Iversen L, et al. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). J Eur Acad Dermatol Venereol. 2019;33(2):340-354. doi: 10.1111/jdv.15252</mixed-citation><mixed-citation xml:lang="en">Tveit KS, Duvetorp A, Østergaard M, Skov L, Danielsen K, Iversen L, et al. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). J Eur Acad Dermatol Venereol. 2019;33(2):340-354. doi: 10.1111/jdv.15252</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US Perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic ARTHRITIS (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87-97. doi: 10.1007/s40257-015-0169-x</mixed-citation><mixed-citation xml:lang="en">Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US Perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic ARTHRITIS (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87-97. doi: 10.1007/s40257-015-0169-x</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kilic L, Erden A, Bingham CO 3rd, Gossec L, Kalyoncu U. The reporting of patient-reported outcomes in studies of patients with rheumatoid arthritis: A systematic review of 250 articles. J Rheumatol. 2016;43(7):1300-1305. doi: 10.3899/jrheum.151177</mixed-citation><mixed-citation xml:lang="en">Kilic L, Erden A, Bingham CO 3rd, Gossec L, Kalyoncu U. The reporting of patient-reported outcomes in studies of patients with rheumatoid arthritis: A systematic review of 250 articles. J Rheumatol. 2016;43(7):1300-1305. doi: 10.3899/jrheum.151177</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – A systematic review and network meta-analysis. Health Qual Life Outcomes. 2014;12:102. doi: 10.1186/1477-7525-12-102</mixed-citation><mixed-citation xml:lang="en">Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – A systematic review and network meta-analysis. Health Qual Life Outcomes. 2014;12:102. doi: 10.1186/1477-7525-12-102</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Almeida C, Choy EH, Hewlett S, Kirwan JR, Cramp F, Chalder T, et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev. 2016;2016(6):CD008334. doi: 10.1002/14651858.CD008334.pub2</mixed-citation><mixed-citation xml:lang="en">Almeida C, Choy EH, Hewlett S, Kirwan JR, Cramp F, Chalder T, et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev. 2016;2016(6):CD008334. doi: 10.1002/14651858.CD008334.pub2</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Barra L, Ha A, Sun L, Fonseca C, Pope J. Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis: A meta-analysis with indirect comparisons. Clin Exp Rheumatol. 2014;32(3):333-341.</mixed-citation><mixed-citation xml:lang="en">Barra L, Ha A, Sun L, Fonseca C, Pope J. Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis: A meta-analysis with indirect comparisons. Clin Exp Rheumatol. 2014;32(3):333-341.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Лила АМ, Паневин ТС, Потапова АС, Семашко АС, Бобкова АО, и др. Динамика показателей, оцениваемых самим пациентом, при использовании различных генно-инженерных биологических препаратов при ревматоидном артрите. Научно-практическая ревматология. 2022;60(4):427-437. doi: 10.47360/1995-4484-2022-427-437</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Lila AM, Panevin TS, Potapova AS, Semashko AS, Bobkova AO, et al. Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):427-437 (In Russ.). doi: 10.47360/1995-4484-2022-427-437</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Strand V, Kaine J, Alten R, Wallenstein G, Diehl A, Shi H, et al. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: A post hoc analysis of data from phase 3 trials of tofacitinib. Arthritis Res Ther. 2020;22(1):243. doi: 10.1186/s13075-020-02324-7</mixed-citation><mixed-citation xml:lang="en">Strand V, Kaine J, Alten R, Wallenstein G, Diehl A, Shi H, et al. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: A post hoc analysis of data from phase 3 trials of tofacitinib. Arthritis Res Ther. 2020;22(1):243. doi: 10.1186/s13075-020-02324-7</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Исходы лечения, оцениваемые самим пациентом, – новая философия анализа эффективности терапии при иммуновоспалительных заболеваниях. Современная ревматология. 2021;15(5):121-127. doi: 10.14412/1996-7012-2021-5-121-127</mixed-citation><mixed-citation xml:lang="en">Patient’s reported outcomes – a new philosophy for analyzing the effectiveness of therapy in immunoinflammatory diseases. Modern Rheumatology Journal. 2021;15(5):121-127 (In Russ.). doi: 10.14412/1996-7012-2021-5-121-127</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Keystone E, Movahedi M, Cesta A, Bombardier C, Sampalis JS, Rampakakis E. Differential influence of Clinical Disease Activity Index components based on disease state in rheumatoid arthritis patients: Real-world results from the Ontario Best Practices Research Initiative. Clin Exp Rheumatol. 2022;40(11):2147-2152. doi: 10.55563/clinexprheumatol/86frzq</mixed-citation><mixed-citation xml:lang="en">Keystone E, Movahedi M, Cesta A, Bombardier C, Sampalis JS, Rampakakis E. Differential influence of Clinical Disease Activity Index components based on disease state in rheumatoid arthritis patients: Real-world results from the Ontario Best Practices Research Initiative. Clin Exp Rheumatol. 2022;40(11):2147-2152. doi: 10.55563/clinexprheumatol/86frzq</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Brkic A, Łosińska K, Pripp AH, Korkosz M, Haugeberg G. Remission or not remission, that’s the question: Shedding light on remission and the impact of objective and subjective measures reflecting disease activity in rheumatoid arthritis. Rheumatol Ther. 2022;9(6):1531-1547. doi: 10.1007/s40744-022-00490-5</mixed-citation><mixed-citation xml:lang="en">Brkic A, Łosińska K, Pripp AH, Korkosz M, Haugeberg G. Remission or not remission, that’s the question: Shedding light on remission and the impact of objective and subjective measures reflecting disease activity in rheumatoid arthritis. Rheumatol Ther. 2022;9(6):1531-1547. doi: 10.1007/s40744-022-00490-5</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Duarte C, Ferreira RJO, Santos EJF, da Silva JAP. Treatingto-target in rheumatology: Theory and practice. Best Pract Res Clin Rheumatol. 2022;36(1):101735. doi: 10.1016/j.berh.2021.101735</mixed-citation><mixed-citation xml:lang="en">Duarte C, Ferreira RJO, Santos EJF, da Silva JAP. Treatingto-target in rheumatology: Theory and practice. Best Pract Res Clin Rheumatol. 2022;36(1):101735. doi: 10.1016/j.berh.2021.101735</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Погожева ЕЮ, Амирджанова ВН, Филатова ЕС, Нестеренко ВА. «Мне стало лучше» и «мне стало хорошо»: поиск объективного критерия клинического ответа на анальгетическую терапию при ревматических заболеваниях. Современная ревматология. 2020;14(2):90-96. doi: 10.14412/1996-7012-2020-2-90-96</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Pogozheva EYu, Amirdzanova VN, Filatova ES, Nesterenko VA. «I am getting better» and «I feel good»: Searching for an objective criterion for a clinical response to analgesic therapy for rheumatic diseases. Modern Rheumatology Journal. 2020;14(2):90-96 (In Russ.). doi: 10.14412/1996-7012-2020-2-90-96</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Tubach F, Wells GA, Ravaud P, Dougados M. Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: Methodological issues. J Rheumatol. 2005;32(10):2025-2029.</mixed-citation><mixed-citation xml:lang="en">Tubach F, Wells GA, Ravaud P, Dougados M. Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: Methodological issues. J Rheumatol. 2005;32(10):2025-2029.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: The patient acceptable symptom state. Ann Rheum Dis. 2005;64(1):34-37. doi: 10.1136/ard.2004.023028</mixed-citation><mixed-citation xml:lang="en">Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: The patient acceptable symptom state. Ann Rheum Dis. 2005;64(1):34-37. doi: 10.1136/ard.2004.023028</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Tubach F, Pham T, Skomsvoll JF, Mikkelsen K, Bjørneboe O, Ravaud P, et al. Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis. Arthritis Rheum. 2006;55(6):960-963. doi: 10.1002/art.22342</mixed-citation><mixed-citation xml:lang="en">Tubach F, Pham T, Skomsvoll JF, Mikkelsen K, Bjørneboe O, Ravaud P, et al. Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis. Arthritis Rheum. 2006;55(6):960-963. doi: 10.1002/art.22342</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Felson DT, et al. Minimal clinically important improvement and pa tient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol. 2007;34(5):1188-1193.</mixed-citation><mixed-citation xml:lang="en">Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Felson DT, et al. Minimal clinically important improvement and pa tient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol. 2007;34(5):1188-1193.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Puyraimond-Zemmour D, Etcheto A, Fautrel B, Balanescu A, de Wit M, Heiberg T, et al. Associations between five important domains of health and the patient acceptable symptom state in rheumatoid arthritis and psoriatic arthritis: A cross-sectional study of 977 patients. Arthritis Care Res (Hoboken). 2017; 69(10):1504-1509. doi: 10.1002/acr.23176</mixed-citation><mixed-citation xml:lang="en">Puyraimond-Zemmour D, Etcheto A, Fautrel B, Balanescu A, de Wit M, Heiberg T, et al. Associations between five important domains of health and the patient acceptable symptom state in rheumatoid arthritis and psoriatic arthritis: A cross-sectional study of 977 patients. Arthritis Care Res (Hoboken). 2017; 69(10):1504-1509. doi: 10.1002/acr.23176</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Tubach F, Ravaud P, Martin-Mola E, Awada H, Bellamy N, Bombardier C, et al. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res (Hoboken). 2012;64(11):1699-1707. doi: 10.1002/acr.21747</mixed-citation><mixed-citation xml:lang="en">Tubach F, Ravaud P, Martin-Mola E, Awada H, Bellamy N, Bombardier C, et al. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res (Hoboken). 2012;64(11):1699-1707. doi: 10.1002/acr.21747</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Gwinnutt JM, Hyrich KL, Lunt M; RAMS Co-Investigators, Barton A, Verstappen SMM. Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as ‘satisfactory’. Rheumatology (Oxford). 2020;59(8):1853-1861. doi: 10.1093/rheumatology/kez497</mixed-citation><mixed-citation xml:lang="en">Gwinnutt JM, Hyrich KL, Lunt M; RAMS Co-Investigators, Barton A, Verstappen SMM. Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as ‘satisfactory’. Rheumatology (Oxford). 2020;59(8):1853-1861. doi: 10.1093/rheumatology/kez497</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Duarte C, Santos E, Kvien TK, Dougados M, de Wit M, Gossec L, et al. Attainment of the patient-acceptable symptom state in 548 patients with rheumatoid arthritis: Influence of demographic factors. Joint Bone Spine. 2021;88(1):105071. doi: 10.1016/j.jbspin.2020.09.003</mixed-citation><mixed-citation xml:lang="en">Duarte C, Santos E, Kvien TK, Dougados M, de Wit M, Gossec L, et al. Attainment of the patient-acceptable symptom state in 548 patients with rheumatoid arthritis: Influence of demographic factors. Joint Bone Spine. 2021;88(1):105071. doi: 10.1016/j.jbspin.2020.09.003</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Stocker PH, Jasper MH, Kahlow B, Nisihara R, Skare T. Depression as a major determinant of PASS (Patient’s Acceptable Symptoms State) in rheumatoid arthritis: a cross-sectional study in Brazilian patients. Rev Assoc Med Bras (1992). 2022;68(8):995-999. doi: 10.1590/1806-9282.20220600</mixed-citation><mixed-citation xml:lang="en">Stocker PH, Jasper MH, Kahlow B, Nisihara R, Skare T. Depression as a major determinant of PASS (Patient’s Acceptable Symptoms State) in rheumatoid arthritis: a cross-sectional study in Brazilian patients. Rev Assoc Med Bras (1992). 2022;68(8):995-999. doi: 10.1590/1806-9282.20220600</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Heiberg T, Kvien TK, Mowinckel P, Aletaha D, Smolen JS, Hagen KB. Identification of disease activity and health status cutoff points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(7):967-971. doi: 10.1136/ard.2007.077503</mixed-citation><mixed-citation xml:lang="en">Heiberg T, Kvien TK, Mowinckel P, Aletaha D, Smolen JS, Hagen KB. Identification of disease activity and health status cutoff points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(7):967-971. doi: 10.1136/ard.2007.077503</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Katchamart W, Narongroeknawin P, Suppa-Udom B, Chanapai W, Srisomnuek A. Factors associated with and cutoff points for Patient Acceptable Symptom State (PASS) in rheumatoid arthritis. Clin Rheumatol. 2020;39(3):779-786. doi:10.1007/s10067-019-04860-3</mixed-citation><mixed-citation xml:lang="en">Katchamart W, Narongroeknawin P, Suppa-Udom B, Chanapai W, Srisomnuek A. Factors associated with and cutoff points for Patient Acceptable Symptom State (PASS) in rheumatoid arthritis. Clin Rheumatol. 2020;39(3):779-786. doi:10.1007/s10067-019-04860-3</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Полищук ЕЮ, Потапова АС, Матьянова ЕВ, Семашко АС, Бобкова АО, и др. Результаты назначения генноинженерных биологических препаратов и ингибиторов Янускиназ при ревматоидном артрите в период пандемии коронавирусной болезни COVID-19: данные телефонного опроса 254 пациентов. Научно-практическая ревматология. 2022; 60(2):149-156. doi: 10.47360/1995-4484-2022-149-156</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Polishchuk EYu, Potapova AS, Matya nova EV, Semashko AS, Bobkova АO, et al. The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: Data from a telephone survey of 254 patients. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(2):149-156 (In Russ.). doi: 10.47360/1995-4484-2022-149-156</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Migliore A, Gigliucci G, Alekseeva L, Avasthi S, Bannuru RR, Chevalier X, et al. Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements. Ther Adv Musculoskelet Dis. 2019;11:1759720X19893800. doi: 10.1177/1759720X19893800</mixed-citation><mixed-citation xml:lang="en">Migliore A, Gigliucci G, Alekseeva L, Avasthi S, Bannuru RR, Chevalier X, et al. Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements. Ther Adv Musculoskelet Dis. 2019;11:1759720X19893800. doi: 10.1177/1759720X19893800</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Uhrenholt L, Høstgaard S, Pedersen JF, Christensen R, Dreyer L, Leffers HCB, et al. Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement study. Lupus. 2021;30(13):2124-2134. doi: 10.1177/09612033211051641</mixed-citation><mixed-citation xml:lang="en">Uhrenholt L, Høstgaard S, Pedersen JF, Christensen R, Dreyer L, Leffers HCB, et al. Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement study. Lupus. 2021;30(13):2124-2134. doi: 10.1177/09612033211051641</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">de Wolff L, Vissink A, van Nimwegen JF, van Zuiden G, Mossel E, Olie L, et al. Patient Acceptable Symptom State (PASS) in patients with primary Sjögren’s syndrome in daily clinical practice. Clin Exp Rheumatol. 2022;40(12):2303-2309. doi: 10.55563/clinexprheumatol/mnqiy9</mixed-citation><mixed-citation xml:lang="en">de Wolff L, Vissink A, van Nimwegen JF, van Zuiden G, Mossel E, Olie L, et al. Patient Acceptable Symptom State (PASS) in patients with primary Sjögren’s syndrome in daily clinical practice. Clin Exp Rheumatol. 2022;40(12):2303-2309. doi: 10.55563/clinexprheumatol/mnqiy9</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Lorenzin M, Ughi N, Ariani A, Raffeiner B, Frallonardo P, Hoxha A, et al.; SIR Study Group ATTACk. Predictors of disease activity in gout: A 12-month analysis of the ATTACk (Achieving improvement in the management of crystal-induced arthritis) multicentre cohort study. Clin Exp Rheumatol. 2023;41(3):628-633. doi: 10.55563/clinexprheumatol/eh0jcp</mixed-citation><mixed-citation xml:lang="en">Lorenzin M, Ughi N, Ariani A, Raffeiner B, Frallonardo P, Hoxha A, et al.; SIR Study Group ATTACk. Predictors of disease activity in gout: A 12-month analysis of the ATTACk (Achieving improvement in the management of crystal-induced arthritis) multicentre cohort study. Clin Exp Rheumatol. 2023;41(3):628-633. doi: 10.55563/clinexprheumatol/eh0jcp</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Daste C, Abdoul H, Foissac F, Lefèvre-Colau MM, Poiraudeau S, Rannou F, et al. Patient acceptable symptom state for patientreported outcomes in people with non-specific chronic low back pain. Ann Phys Rehabil Med. 2022;65(1):101451. doi: 10.1016/j.rehab.2020.10.005</mixed-citation><mixed-citation xml:lang="en">Daste C, Abdoul H, Foissac F, Lefèvre-Colau MM, Poiraudeau S, Rannou F, et al. Patient acceptable symptom state for patientreported outcomes in people with non-specific chronic low back pain. Ann Phys Rehabil Med. 2022;65(1):101451. doi: 10.1016/j.rehab.2020.10.005</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor PC. Adopting PROs in virtual and outpatient management of RA. Nat Rev Rheumatol. 2020;16(9):477-478. doi: 10.1038/s41584-020-0449-6</mixed-citation><mixed-citation xml:lang="en">Taylor PC. Adopting PROs in virtual and outpatient management of RA. Nat Rev Rheumatol. 2020;16(9):477-478. doi: 10.1038/s41584-020-0449-6</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Seppen BF, Verkleij SJ, Wiegel J, Ter Wee MM, Nurmohamed MT, Bos WH. Probability of medication intensifications in rheumatoid arthritis patients with low disease activity scores on their patient-reported outcomes: A medical-records review study. J Clin Rheumatol. 2022;28(8):397-401. doi: 10.1097/RHU.0000000000001883</mixed-citation><mixed-citation xml:lang="en">Seppen BF, Verkleij SJ, Wiegel J, Ter Wee MM, Nurmohamed MT, Bos WH. Probability of medication intensifications in rheumatoid arthritis patients with low disease activity scores on their patient-reported outcomes: A medical-records review study. J Clin Rheumatol. 2022;28(8):397-401. doi: 10.1097/RHU.0000000000001883</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Nowell WB, Gavigan K, Kannowski CL, Cai Z, Hunter T, Venkatachalam S, et al. Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower. Arthritis Res Ther. 2021;23(1):53. doi: 10.1186/s13075-021-02430-0</mixed-citation><mixed-citation xml:lang="en">Nowell WB, Gavigan K, Kannowski CL, Cai Z, Hunter T, Venkatachalam S, et al. Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower. Arthritis Res Ther. 2021;23(1):53. doi: 10.1186/s13075-021-02430-0</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Fautrel B, Alten R, Kirkham B, de la Torre I, Durand F, Barry J, et al. Call for action: How to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int. 2018;38(6):935-947. doi: 10.1007/s00296-018-4005-5</mixed-citation><mixed-citation xml:lang="en">Fautrel B, Alten R, Kirkham B, de la Torre I, Durand F, Barry J, et al. Call for action: How to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int. 2018;38(6):935-947. doi: 10.1007/s00296-018-4005-5</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Uhrenholt L, Christensen R, Dreyer L, Schlemmer A, Hauge EM, Krogh NS, et al. Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis: A randomized, crossover, agreement study. Scand J Rheumatol. 2022;51(1):25-33. doi: 10.1080/03009742.2021.1907925</mixed-citation><mixed-citation xml:lang="en">Uhrenholt L, Christensen R, Dreyer L, Schlemmer A, Hauge EM, Krogh NS, et al. Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis: A randomized, crossover, agreement study. Scand J Rheumatol. 2022;51(1):25-33. doi: 10.1080/03009742.2021.1907925</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Duarte C, Santos E, da Silva JAP, Kristianslund EK, Kvien TK, Dougados M, et al. The Patient Experienced Symptom State (PESS): A patient-reported global outcome measure that may better reflect disease remission status. Rheumatology (Oxford). 2020;59(11):3458-3467. doi: 10.1093/rheumatology/keaa149</mixed-citation><mixed-citation xml:lang="en">Duarte C, Santos E, da Silva JAP, Kristianslund EK, Kvien TK, Dougados M, et al. The Patient Experienced Symptom State (PESS): A patient-reported global outcome measure that may better reflect disease remission status. Rheumatology (Oxford). 2020;59(11):3458-3467. doi: 10.1093/rheumatology/keaa149</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
